期刊
CELLS
卷 10, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cells10061511
关键词
immunotherapy; chimeric receptor; NK cells
类别
资金
- Ministry of Science and Higher Education [DI2014007344]
- European Research Council [805038/STIMUNO/ERC-2018-STG]
- Polish National Science Centre [2015/19/B/NZ6/02862, 2019/03/X/NZ4/01528, 2019/35/D/NZ5/01191]
- Ministry of Science and Higher Education within Regional Initiative of Excellence program [013/RID/2018/19]
Despite the availability of treatments that can cure hematological malignancies, their implementation is limited by patient age and frailty, and they often come with undesirable side effects. Therefore, cell-based immunotherapy may be the optimal strategy to be successfully incorporated into standard treatment protocols in the future.
Despite the introduction of a plethora of different anti-neoplastic approaches including standard chemotherapy, molecularly targeted small-molecule inhibitors, monoclonal antibodies, and finally hematopoietic stem cell transplantation (HSCT), there is still a need for novel therapeutic options with the potential to cure hematological malignancies. Although nowadays HSCT already offers a curative effect, its implementation is largely limited by the age and frailty of the patient. Moreover, its efficacy in combating the malignancy with graft-versus-tumor effect frequently coexists with undesirable graft-versus-host disease (GvHD). Therefore, it seems that cell-based adoptive immunotherapies may constitute optimal strategies to be successfully incorporated into the standard therapeutic protocols. Thus, modern cell-based immunotherapy may finally represent the long-awaited magic bullet against cancer. However, enhancing the safety and efficacy of this treatment regimen still presents many challenges. In this review, we summarize the up-to-date state of the art concerning the use of CAR-T cells and NK-cell-based immunotherapies in hemato-oncology, identify possible obstacles, and delineate further perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据